Notifications
Back
Media Center

[Press Release]PharmAbcine announces the execution of a Material Cooperative Research and Development Agreement (MCRADA)...

20 Aug 2020
Title
PharmAbcine announces the execution of a Material Cooperative Research and Development Agreement (MCRADA) with the NIH to evaluate the efficacy of PMC-403 to treat SCLS PharmAbcineLogo (PRNewsfoto/PharmAbcine)
Category
Press Release


PharmAbcine signs a research collaboration agreement with Wuxi Shuangliang Biotechnology (SLBio) to evaluate a combination therapy to treat NSCLC





please visit the website at

https://www.prnewswire.com/news-releases/pharmabcine-signs-a-research-collaboration-agreement-with-wuxi-shuangliang-biotechnology-slbio-to-evaluate-a-combination-therapy-to-treat-nsclc-301104429.html

PharmAbcine is presenting at the KSMO 2020 PharmAbcine Present Preclinical Data of Blood Vessel Stabilizing PMC-403 at 2020 AACR E-poster
List New post




     2F, Research Building 2, 70,

     Yuseong-daero 1689 beon-gil,
     Yuseong-gu, Daejeon, 34047, Republic of Korea


     HQ +82-42-863-2017 

     R&D Center +82-42-861-2017

     Investor Relations +70-4294-6097 

     FAX +82-42-863-2080 


     COPYRIGHT BY PharmAbcine Inc.

     ALL RIGHTS RESERVE